UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Effect of tear osmolarity on repeatability of keratometry for cataract surgery planning

Journal of cataract and refractive surgery, 2015-08, Vol.41 (8), p.1672-1677

2015

Volltextzugriff (PDF)

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2)

Ophthalmology (Rochester, Minn.), 2023-10, Vol.130 (10), p.1015-1023

2023

Volltextzugriff (PDF)

NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study

Ophthalmology (Rochester, Minn.), 2023-05, Vol.130 (5), p.516-524

2023

Volltextzugriff (PDF)

The impact of Demodex blepharitis on patient symptoms and daily life

Optometry and vision science, 2024-03, Vol.101 (3), p.151

2024

Volltextzugriff (PDF)

Lirentelimab for severe and chronic forms of allergic conjunctivitis

Journal of allergy and clinical immunology, 2022-09, Vol.150 (3), p.631-639

2022

Volltextzugriff (PDF)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

Clinical ophthalmology (Auckland, N.Z.), 2021-01, Vol.15, p.3679-3686

2021

Volltextzugriff (PDF)

An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial

The ocular surface, 2020-01, Vol.18 (1), p.148-157

2020

Volltextzugriff (PDF)

Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model

Clinical therapeutics, 2002-06, Vol.24 (6), p.918-929

2002

Volltextzugriff (PDF)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study

Clinical ophthalmology (Auckland, N.Z.), 2012-01, Vol.6 (default), p.855-863

2012

Volltextzugriff (PDF)

Ocular allergic disorders: Disease entities and differential diagnoses

Current allergy and asthma reports, 2009-07, Vol.9 (4), p.297-303

2009

Volltextzugriff (PDF)

Evaluation of the efficacy of Olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model

Clinical therapeutics, 2001-08, Vol.23 (8), p.1272-1280

2001

Volltextzugriff (PDF)

A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model

Clinical therapeutics, 2000-07, Vol.22 (7), p.826-833

2000

Volltextzugriff (PDF)

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis

Ophthalmology (Rochester, Minn.), 2023-10, Vol.130 (10), p.1015-1023

2023

Volltextzugriff (PDF)

Clinical safety and efficacy of bepotastine besilate ophthalmic solution to treat allergic conjunctivitis

Expert review of ophthalmology, 2010-10, Vol.5 (5), p.595-602

2010

Volltextzugriff (PDF)

Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis

Advances in therapy, 2007-11, Vol.24 (6), p.1221-1232

2007

Volltextzugriff (PDF)

Determinants of Outcomes of Adenoviral Keratoconjunctivitis

Ophthalmology (Rochester, Minn.), 2018-09, Vol.125 (9), p.1344-1353

2018

Volltextzugriff (PDF)

NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction

Ophthalmology (Rochester, Minn.), 2023-05, Vol.130 (5), p.516-524

2023

Volltextzugriff (PDF)

Lacripep for the Treatment of Primary Sjögren-Associated Ocular Surface Disease: Results of the First-In-Human Study

Cornea, 2023-07, Vol.42 (7), p.847

2023

Volltextzugriff (PDF)

Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: A pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies

Journal of ocular pharmacology and therapeutics, 2002-10, Vol.18 (5), p.475-488

2002

Volltextzugriff (PDF)

Ocular allergic disease in the senior patient: diagnosis and management

Allergy and asthma proceedings, 2000-09, Vol.21 (5), p.277

Berdy, G J

2000

Volltextzugriff (PDF)

Machine Learning Prediction of Adenovirus D8 Conjunctivitis Complications from Viral Whole-Genome Sequence

Ophthalmology science (Online), 2022-12, Vol.2 (4), p.100166, Article 100166

2022

Volltextzugriff (PDF)

The author replies

Clinical therapeutics, 2002-09, Vol.24 (9), p.1478-1480

Berdy, Gregg J.

2002

Volltextzugriff (PDF)

The author replies

Clinical therapeutics, 2002, Vol.24 (9), p.1478-1480

Berdy, Gregg J.

2002

Volltextzugriff (PDF)

Evaluation of the efficacy of olapatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model

Clinical therapeutics, 2001-08, Vol.23 (8), p.1272-1280

2001

Volltextzugriff (PDF)

EHR brings tangible benefits

Ophthalmology Times, 2013-10, Vol.38 (19), p.48

Berdy, Gregg J

2013

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(26)

Publikationsform

Sprache

Englisch
(37)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Ophthalmology
(23)
Humans
(21)
Biological And Medical Sciences
(9)
Conjunctivitis, Allergic - Drug Therapy
(9)
Double-Blind Method
(9)
Medical Sciences
(9)
Female
(8)
Male
(8)
Middle Aged
(7)
Adult
(6)
Aged
(6)
Ocular Allergy
(6)
Pharmacology & Pharmacy
(6)
Pharmacology. Drug Treatments
(6)
Prospective Studies
(6)
Anti-Allergic Agents - Therapeutic Use
(5)
Conjunctival Allergen Challenge
(5)
Cornea
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of tear osmolarity on repeatability of keratometry for cataract surgery planning

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2)

NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study

The impact of Demodex blepharitis on patient symptoms and daily life

Lirentelimab for severe and chronic forms of allergic conjunctivitis

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial

Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study

Ocular allergic disorders: Disease entities and differential diagnoses

Evaluation of the efficacy of Olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model

A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis

Clinical safety and efficacy of bepotastine besilate ophthalmic solution to treat allergic conjunctivitis

Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis

Determinants of Outcomes of Adenoviral Keratoconjunctivitis

NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction

Lacripep for the Treatment of Primary Sjögren-Associated Ocular Surface Disease: Results of the First-In-Human Study

Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: A pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies

Ocular allergic disease in the senior patient: diagnosis and management

Machine Learning Prediction of Adenovirus D8 Conjunctivitis Complications from Viral Whole-Genome Sequence

The author replies

The author replies

Evaluation of the efficacy of olapatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model

EHR brings tangible benefits

Suchergebnisse filtern